The interim Phase 2 data for GX-03 in atopic dermatitis is compelling with strong efficacy and clean safety, positioning it as a potential best-in-class topical. The mid-2026 topline readout is the next major catalyst. Monitor enrollment progress and any Type B meeting outcomes with FDA. The onychomycosis program adds pipeline optionality but is earlier stage.
Price Chart
Executive Summary
Turn Therapeutics released an updated investor presentation at the Jefferies Global Healthcare Conference, disclosing positive interim Phase 2 data for GX-03 in moderate-to-severe atopic dermatitis. The data showed a 79.43% mean EASI reduction at Week 4 vs 50.55% for vehicle, with zero serious adverse events. The company also highlighted a Phase 3-ready onychomycosis program and provided financial guidance including $11M cash as of March 31, 2026, with runway into Q1 2027.
Key Facts
- GX-03 showed 79.43% mean EASI reduction at Week 4 vs 50.55% for vehicle (28.88% difference) in Phase 2 interim analysis
- Zero serious adverse events reported; only 1 mild AE in GX-03 arm (pleasant warming sensation)
- EASI-75 achieved by 70.4% of GX-03 patients at Week 4 vs 56.5% for vehicle
- EASI-100 (complete clearance) achieved by 18.5% of GX-03 patients at Week 4 vs 4.3% for vehicle
- Phase 2 adaptive trial ongoing; topline results expected mid-2026
- Onychomycosis program Phase 3 ready with ~85% efficacy in Phase 2 equivalent study
- Cash balance of $11M as of March 31, 2026; cash runway into Q1 2027
- ~30M common shares outstanding as of March 31, 2026
- 17 issued patents with coverage through 2037
- Total money raised since inception (2015): $29M
Financial Impact
No revenue or earnings reported. Cash balance $11M with runway into Q1 2027. Expected R&D spend of $55-60M for Phase 3 trials on both indications.
Risk Factors
- Phase 2 data is interim and from a small sample (N=50); final results may differ
- Cash runway only into Q1 2027; likely need for additional capital to fund Phase 3 trials
- Competitive landscape includes approved topicals (JAK/PDE4 inhibitors) and biologics
- No head-to-head data vs approved therapies; comparisons are cross-trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-064405 |
| Document: ea0293128-8k_turn.htm | 0001213900-26-064405 |
| Document: 0001213900-26-064405-index-headers.html | 0001213900-26-064405 |
| Document: 0001213900-26-064405-index.html | 0001213900-26-064405 |
| Document: 0001213900-26-064405.txt | 0001213900-26-064405 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.47 | awaiting T+60 | — | $10.47 (+0.00%) |
Oct 6, 2026 20d ago | 8-K | $12.10 | awaiting T+60 | — | $10.47 (−13.47%) |
Sep 10, 2026 6w ago | 8-K | $13.38 | awaiting T+60 | — | $10.47 (−21.75%) |
Sep 9, 2026 6w ago | 8-K | $13.75 | awaiting T+60 | — | $10.47 (−23.85%) |
Aug 18, 2026 10w ago | 8-K | $9.99 | awaiting T+60 | — | $10.47 (+4.80%) |
Jul 7, 2026 16w ago | 8-K | $9.71 $14.39 | ▲ +48.20% | ▲ +46.20% | $10.47 (+7.83%) |
Jun 3, 2026 20w ago | 8-K | $6.02 $10.11 | ▲ +67.94% | ▲ +65.44% | $10.47 (+73.92%) |
Jun 1, 2026 21w ago | 8-K | $6.33 $9.73 | ▲ +53.71% | ▲ +52.48% | $10.47 (+65.40%) |
May 27, 2026 21w ago | 8-K | $5.29 $9.54 | ▲ +80.34% | ▲ +78.46% | $10.47 (+97.92%) |
May 19, 2026 23w ago | 8-K | $4.55 $9.86 | ▲ +116.70% | ▲ +110.41% | $10.47 (+130.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers